Bergman R N
Department of Physiology and Biophysics, University of Southern California Medical School, Los Angeles 90033.
Diabetes. 1989 Dec;38(12):1512-27. doi: 10.2337/diab.38.12.1512.
Glucose tolerance depends on a complex interaction among insulin secretion from the beta-cells, clearance of the hormone, and the actions of insulin to accelerate glucose disappearance and inhibit endogenous glucose production. An additional factor, less well recognized, is the ability of glucose per se, independent of changes in insulin, to increase glucose uptake and suppress endogenous output (glucose effectiveness). These factors can be measured in the intact organism with physiologically based minimal models of glucose utilization and insulin kinetics. With the glucose minimal model, insulin sensitivity (SI) and glucose effectiveness (SG) are measured by computer analysis of the frequently sampled intravenous glucose tolerance test. The test involves intravenous injection of glucose followed by tolbutamide or insulin and frequent blood sampling. SI varied from a high of 7.6 x 10(-4) min-1.microU-1.ml-1 in young Whites to 2.3 x 10(-4) min-1.microU-1.ml-1 in obese nondiabetic subjects; in all of the nondiabetic subjects, SG was normal. In subjects with non-insulin-dependent diabetes mellitus (NIDDM), not only was SI reduced 90% below normal (0.61 +/- 0.16 x 10(-4) min-1.microU-1.ml-1), but in this group alone, SG was reduced (from 0.026 +/- 0.008 to 0.014 +/- 0.002 min-1); thus, defects in SI and SG are synergistic in causing glucose intolerance in NIDDM. One assumption of the minimal model is that the time delay in insulin action on glucose utilization in vivo is due to sluggish insulin transport across the capillary endothelium. This was tested by comparing insulin concentrations in plasma with those in lymph (representing interstitial fluid) during euglycemic-hyperinsulinemic glucose clamps. Lymph insulin was lower than plasma insulin at basal (12 vs. 18 microU/ml) and at steady state, indicating significant loss of insulin from the interstitial space, presumably due to cellular uptake of the insulin-receptor complex. Additionally, during clamps, lymph insulin changed more slowly than plasma insulin, but the rate of glucose utilization followed a time course identical with that of lymph (r = .96) rather than plasma (r = .71). Thus, lymph insulin, which may be reflective of interstitial fluid, is the signal to which insulin-sensitive tissues are responding. These studies support the concept that, at physiological insulin levels, the time for insulin to cross the capillary endothelium is the process that determines the rate of insulin action in vivo.(ABSTRACT TRUNCATED AT 400 WORDS)
葡萄糖耐量取决于β细胞分泌胰岛素、激素清除以及胰岛素促进葡萄糖消失和抑制内源性葡萄糖生成的作用之间的复杂相互作用。另一个较少被认识的因素是葡萄糖本身独立于胰岛素变化而增加葡萄糖摄取和抑制内源性输出的能力(葡萄糖效能)。这些因素可以通过基于生理学的葡萄糖利用和胰岛素动力学最小模型在完整机体中进行测量。使用葡萄糖最小模型,通过对频繁采样的静脉葡萄糖耐量试验进行计算机分析来测量胰岛素敏感性(SI)和葡萄糖效能(SG)。该试验包括静脉注射葡萄糖,随后注射甲苯磺丁脲或胰岛素,并频繁采集血样。SI在年轻白人中高达7.6×10⁻⁴分钟⁻¹·微单位⁻¹·毫升⁻¹,在肥胖非糖尿病受试者中为2.3×10⁻⁴分钟⁻¹·微单位⁻¹·毫升⁻¹;在所有非糖尿病受试者中,SG均正常。在非胰岛素依赖型糖尿病(NIDDM)患者中,不仅SI比正常水平降低了90%(0.61±0.16×10⁻⁴分钟⁻¹·微单位⁻¹·毫升⁻¹),而且仅在该组中,SG也降低了(从0.026±0.008降至0.014±0.002分钟⁻¹);因此,SI和SG缺陷在导致NIDDM患者葡萄糖不耐受方面具有协同作用。最小模型的一个假设是,胰岛素在体内对葡萄糖利用作用的时间延迟是由于胰岛素跨毛细血管内皮转运缓慢所致。通过在正常血糖 - 高胰岛素葡萄糖钳夹期间比较血浆和淋巴液(代表组织间液)中的胰岛素浓度对此进行了测试。基础状态(12对18微单位/毫升)和稳态时,淋巴液胰岛素低于血浆胰岛素,表明胰岛素从组织间隙有显著损失,推测是由于胰岛素 - 受体复合物的细胞摄取。此外,在钳夹期间,淋巴液胰岛素变化比血浆胰岛素慢,但葡萄糖利用率的时间进程与淋巴液(r = 0.96)而非血浆(r = 0.71)相同。因此,可能反映组织间液的淋巴液胰岛素是胰岛素敏感组织所响应的信号。这些研究支持了这样一种概念,即在生理胰岛素水平下胰岛素穿过毛细血管内皮的时间是决定体内胰岛素作用速率的过程。(摘要截断于400字)